Global Plasma Fractionation Market will grow at a CAGR of 7.0% from 2016 to 2020

Date: 2016-09-14

Plasma fractionation refers to the general processes of separating the various components of blood plasma, which in turn is a component of blood obtained through blood fractionation. The plasma fractionation is widely used to neurology, immunology, hematology, pulmonology, hemato-oncology, rheumatology, critical care, and others.

Blood plasma is the liquid component of whole blood, and makes up approximately 55% of the total blood volume. It is composed primarily of water with small amounts of minerals, salts, ions, nutrients, and proteins in solution. In whole blood, red blood cells, leukocytes, and platelets are suspended within the plasma.

The history of plasma fractionation began with the need to develop blood serum products to help soldiers suffering from shock and burns in the Second World War. Dr. Edwin Cohn, of Harvard University, was a key figure involved in the development of a process to separate proteins from human plasma, and the “Cohn fractionation process” which still forms the basis of most modern plasma fractionation facilities bears his name.
The Cohn plasma fractionation process diagram


The global plasma fractionation market is projected to reach USD 24.3 billion by 2020, growing at a CAGR of 7.0% from 2016 to 2020. In terms of region, North America occupies major market share followed by Europe, Asia-Pacific has the highest growth rates within expectations.

Some of the major competitors include Mitsubishi Tanabe (Japan), China Biologic Products, Inc. (China), CSL Ltd. (Australia), Baxter (U.S.), Octapharma AG (Switzerland), GRIFOLS MOVACO, S.A. (Spain), Bio Products Laboratory Ltd. (BPL) (UK), Kedrion S.p.A. (ITALY), Sanquin (Netherlands) and others.

Read Full Report:

Joanna | Executive – International Business and partner Relations
E-mail: | Tel: 1-510-400-8520


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample